Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Theriva Biologics Inc

TOVX ✗ NOT COMPLIANT ☆ Track — members

NYSE American · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.23

▼ -0.87%

Market Cap $10.46M · Vol 48.87K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$10.46M

Micro Cap

Div Yield

N/A

EPS Growth

+88.70%

YoY

RSI (14)

60.11

Momentum

Beta

1.15

vs Market

52W High

$0.86

73.58% below

52W Low

$0.16

39.79% above

Volume

48.87K

Avg 43.12K

P/B

0.49

Price-to-book

ROE

N/A

Return on equity

Free Float

98.37%

Public shares

Shariah Compliance8 STANDARDS

✗ Theriva Biologics Inc (TOVX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TOVX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.26%

-5.04%

-28.97%

+25.27%

YTD

+8.37%

-47.59%

-98.34%

-99.81%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-23,739,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-64.52% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.49
P/FCF	N/A
EPS Growth	+88.70%
Outstanding Shares	45.89M

Technical Indicators

50-Day SMA	$0.24
200-Day SMA	$0.24
RSI (14)	60.11
Beta	1.15
52-Week High	$0.86
52-Week Low	$0.16

Volume Today	48.87K
Avg Daily Volume (30D)	43.12K
Relative Volume	1.13x
Volatility (10D)	49.25
Volatility (30D)	54.55
Free Float	98.37%

Analyst Consensus

BUY

Current Price $0.23

Mean Target $2.50

52W Low$0.16 52W High$0.86

Current

Target

$0.16 $0.86

Current Analyst target

+996.49% upside potential · 2 analysts

Identifiers

ExchangeNYSE American

FIGIBBG001S77L07

ISINUS87164U5083

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.